Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
Details : The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.
Brand Name : Trappsol Cyclo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
LOOKING FOR A SUPPLIER?